FastWave Granted 7th Utility PatentFastWave Granted 7th Utility Patent
The patent covers the company’s laser IVL technology, which is specifically being developed to tackle calcified arteries.
January 22, 2025
.png?width=1280&auto=webp&quality=95&format=jpg&disable=upscale)
The patent covers the company’s laser IVL technology, which is specifically being developed to tackle calcified arteries.
FastWave Medical, a developer of advanced intravascular lithotripsy (IVL) technology, announced the issuance of its seventh utility patent by the United States Patent and Trademark Office (USPTO).
This patent covers FastWave's laser IVL technology, specifically engineered to address calcified arteries—a condition affecting millions worldwide and a major challenge in cardiovascular care.
Interventional cardiologists are already recognizing the potential of FastWave's laser technology. "Calcified arteries remain one of the most difficult conditions to treat in our field," said Amir Kaki, MD, an interventional cardiologist at Henry Ford St. John's Hospital, Detroit, MI. "FastWave's laser IVL platform is a compelling advancement that should provide a more precise, efficient, and predictable way to manage complex arterial disease."
FastWave's COO Tristan Tieso added, "Our laser IVL technology continues to push the boundaries of what's possible in treating calcified arteries, getting us closer to our primary goal of helping interventionalists ensure the best care for their patients."
About the Author
You May Also Like